ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 785

Ophthalmic Manifestations Of IgG4-Related Disease:  A Single-Center Experience

Zachary S. Wallace1, Vikram Deshpande2 and John H. Stone3, 1Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Boston, MA, 2Pathology, Massachusetts General Hospital, Boston, MA, 3Rheumatology, Massachusetts General Hospital, Boston, MA

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: IgG4 Related Disease, ocular involvement and rituximab

  • Tweet
  • Email
  • Print
Session Information

Title: Miscellaneous Rheumatic Diseases

Session Type: Abstract Submissions (ACR)

Background/Purpose:

IgG4-related disease (IgG4-RD) is an inflammatory disorder responsible for fibrosing, tumefactive lesions that can present in nearly any anatomic location.  The orbital manifestations of IgG4-RD, termed IgG4-related ophthalmic disease (IgG4-ROD), include lacrimal gland involvement in most cases.  However, the extraocular muscles, orbital soft tissues, sclera, and local nerves may also be affected.  We review the orbital manifestations of IgG4-RD based on the experience at our center and characterize the natural history, pathology, and treatment of these IgG4-RD complications. 

Methods:

We identified 27 patients in our IgG4-RD Registry with orbital manifestations.  Six cases were excluded because no pathology was available for review.  All 21 cases included had histopathologically-confirmed IgG4-RD diagnoses.  We then performed a retrospective medical records review. 

Results:

Patients with IgG4-ROD had a mean age of 50 years (range: 21-79) at the time of symptom onset and were approximately balanced with regard to gender distribution (male 57%, female 43%).The lacrimal gland, affected in 13/21 cases (62%) was the most commonly involved orbital structure.  Dacryoadenitis typically led to proptosis.  Most patients (71%) had bilateral ophthalmic disease as well as extra-orbital involvement.  The salivary glands, abnormal in 40% of those with IgG4-ROD, comprised the most common site of extra-orbital disease.  The average serum IgG4 concentration was 721 mg/dL (range: 28 to 4780; normal < 125).  The mean serum concentration was higher in patients with bilateral disease and in those with extra-orbital manifestations.  Among patients with dacryoadenitis, all were anti-Ro and anti-La negative.  The histopathological and immunostaining features of every biopsy specimen were consistent with consensus criteria.  Nine of 10 patients treated with rituximab responded to this therapy.

Conclusion:

Ophthalmic involvement is a common manifestation of IgG4-RD and can affect nearly every anatomic structure of the orbit.  Consideration of IgG4-RD and accurate diagnosis by biopsy have important implications for prognosis and treatment following the distinction of this condition from Sjögren syndrome (SjS), granulomatosis with polyangiitis (GPA, formerly Wegener’s), sarcoidosis, lymphoma, infection, and other disorders.  Rituximab holds promise as an effective steroid-sparing agent or therapy for steroid-resistant cases.


Disclosure:

Z. S. Wallace,
None;

V. Deshpande,
None;

J. H. Stone,

Genentech and Biogen IDEC Inc.,

5,

Genentech and Biogen IDEC Inc.,

2.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/ophthalmic-manifestations-of-igg4-related-disease-a-single-center-experience/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology